Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.
Fung
J J
JJ
Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania 15213.
Todo
S
S
Tzakis
A
A
Demetris
A
A
Jain
A
A
Abu-Elmaged
K
K
Alessiani
M
M
Starzl
T E
TE
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003524:Cyclosporins / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D016559:Tacrolimus; D014184:Transplantation, Homologous
D000900:Anti-Bacterial Agents; D003524:Cyclosporins; D007166:Immunosuppressive Agents; D016559:Tacrolimus